© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Symtuza
FDA Approves Janssen’s Symtuza for HIV Treatment
Symtuza (darunavir + cobicistat + TAF + emtricitabine) 101
Chart of Approved and Experimental HIV Medications

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Switching Back to Older Tenofovir Improves Lipid Levels

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

Rapid Treatment Works

Starting Symtuza quickly after HIV diagnosis is tied to high viral suppression.

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Rapidly Starting Symtuza After HIV Diagnosis Tied to High Viral Suppression

Researchers enrolled participants within 14 days of their HIV diagnosis.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Switching to New Tenofovir Is Tied to Higher LDL Cholesterol

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

More Good Marks for Janssen’s New HIV Regimen Symtuza

Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.

Switching to Janssen’s Symtuza Is Safe and Effective Up to 96 Weeks

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

FDA Approves Janssen’s Symtuza

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

All the AIDS Conference News That’s Fit to Print

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Symtuza Is a Promising Option for Rapid, Early HIV Treatment

An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.

Switching to Symtuza Is Safe and Effective Regardless of Previous HIV Regimen

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

Janssen’s Experimental Symtuza Performs Well in Those New to HIV Meds

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.

Janssen’s Prezista-Based Regimen Symtuza Suppresses HIV Well

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

Janssen Seeks FDA Approval for Darunavir-Based Combo HIV Tablet

The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.
Advertisement
Treatment News
Features